
ACAD
Healthcare · Biotechnology · $3.24B market cap
$18.75+0.61 (+3.4%)Nov 13, 4:21 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +18.4% over 90 days · 30-day revisions 7 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | After the close | 0.19 | 0.31 | +63.2% |
| Aug 4, 2026 | After the close | 0.06 | 0.18 | +200.0% |
| May 6, 2026 | After the close | 0.08 | 0.02 | -75.0% |
| Mar 2, 2026 | Time not confirmed | 0.14 | 0.14 | -1.0% |
| Nov 5, 2025 | After the close | 0.14 | 0.26 | +85.7% |
| Aug 6, 2025 | After the close | 0.14 | 0.16 | +14.3% |
| May 7, 2025 | After the close | 0.11 | 0.11 | 0.0% |
| Feb 25, 2025 | Before the open | 0.22 | 0.86 | +292.7% |
| Nov 6, 2024 | After the close | 0.14 | 0.20 | +42.9% |
| Aug 6, 2024 | After the close | 0.18 | 0.20 | +11.1% |
| May 8, 2024 | After the close | 0.06 | 0.10 | +66.7% |
| Feb 27, 2024 | After the close | 0.30 | 0.28 | -6.7% |
| Nov 2, 2023 | After the close | -0.42 | -0.40 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the…
| +4.8% |
| Aug 2, 2023 | After the close | -0.12 | 0.01 | +108.3% |
| May 8, 2023 | After the close | -0.21 | -0.27 | -28.6% |
| Feb 27, 2023 | After the close | -0.24 | -0.26 | -8.3% |
| Nov 2, 2022 | After the close | -0.20 | -0.17 | +15.0% |
| Aug 8, 2022 | After the close | -0.25 | -0.21 | +16.0% |
| May 4, 2022 | After the close | -0.60 | -0.70 | -16.7% |
| Feb 28, 2022 | After the close | -0.24 | -0.27 | -12.5% |
| Nov 8, 2021 | After the close | -0.26 | -0.09 | +65.4% |
| Aug 4, 2021 | After the close | -0.30 | -0.27 | +10.0% |
| May 5, 2021 | After the close | -0.53 | -0.42 | +20.8% |
| Feb 24, 2021 | After the close | -0.47 | -0.42 | +10.6% |
| Nov 4, 2020 | After the close | -0.38 | -0.54 | -42.1% |
| Aug 5, 2020 | After the close | -0.43 | -0.27 | +37.2% |
| May 7, 2020 | After the close | -0.48 | -0.57 | -18.8% |
| Feb 26, 2020 | After the close | -0.36 | -0.34 | +5.6% |
| Oct 30, 2019 | After the close | -0.40 | -0.29 | +27.5% |
| Jul 31, 2019 | After the close | -0.46 | -0.38 | +17.4% |
| May 1, 2019 | After the close | -0.53 | -0.59 | -11.3% |
| Feb 26, 2019 | After the close | -0.55 | -0.50 | +9.1% |
| Nov 6, 2018 | After the close | -0.58 | -0.50 | +13.8% |
| Aug 8, 2018 | After the close | -0.45 | -0.51 | -13.3% |
| May 4, 2018 | Before the open | -0.55 | -0.44 | +20.0% |
| Feb 27, 2018 | After the close | -0.57 | -0.55 | +3.5% |